EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy of Clear-Cell Renal-Cell Carcinoma

Sophie Grigolo, Luis Filgueira iD

Cancers · 31.05.2024 · 16 (11) · 2092

DOI: 10.3390/cancers16112092 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.05.2024. Verfasst von Sophie Grigolo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Anatomy, University of Fribourg, 1700 Fribourg, Switzerland. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear-cell Renal-Cell Carcinoma (ccRCC) is the most common type of renal-cell carcinoma (RCC). In many cases, RCC patients manifest the first symptoms during the advanced stage of the disease. For this reason, immunotherapy appears to be one of the dominant treatments to achieve a resolution. In this review, we focus on the presentation of the main immune checkpoint proteins that act as negative regulators of immune responses, such as PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3, and their respective inhibitors. Interleukin-2, another potential component of the treatment of ccRCC patients, has also been covered. The synergy between several immunotherapies is one of the main aspects that unites the conclusions of research in recent years. To date, the combination of several immunotherapies enhances the efficacy of a monotherapy, which often manifests important limitations. Immunotherapy aimed at restoring the anti-cancer immune response in ccRCC, involved in the recognition and elimination of cancer cells, may also be a valid solution for many other types of immunogenic tumors that are diagnosed in the final stages.

Schlagwörter

Stichwörter der Autor:innen

clear-cell renal-cell carcinomaimmune checkpoint proteinsimmunotherapy combinationsinterleukin 2

Autor:innen und Institutionen

  • Anatomy, University of Fribourg, 1700 Fribourg, Switzerland.

ORCID-Profile: Luis Filgueira

Zitieren

APA

Grigolo, S., & Filgueira, L. (2024). Immunotherapy of Clear-Cell Renal-Cell Carcinoma. Cancers, 16(11), 2092. https://doi.org/10.3390/cancers16112092

Vancouver

Grigolo S, Filgueira L. Immunotherapy of Clear-Cell Renal-Cell Carcinoma. Cancers. 2024;16(11):2092. doi:10.3390/cancers16112092

BibTeX
@article{Grigolo2024,
  author = {Grigolo, Sophie and Filgueira, Luis},
  title = {Immunotherapy of Clear-Cell Renal-Cell Carcinoma},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {11},
  pages = {2092},
  doi = {10.3390/cancers16112092}
}
Kostenlos starten →